Cidara Days Of Sales Outstanding from 2010 to 2024

CDTX Stock  USD 20.40  2.95  16.91%   
Cidara Therapeutics Days Of Sales Outstanding yearly trend continues to be fairly stable with very little volatility. Days Of Sales Outstanding is likely to outpace its year average in 2024. During the period from 2010 to 2024, Cidara Therapeutics Days Of Sales Outstanding regression line of annual values had r-squared of  0.23 and arithmetic mean of  41.06. View All Fundamentals
 
Days Of Sales Outstanding  
First Reported
2010-12-31
Previous Quarter
92.79069924
Current Value
110.78
Quarterly Volatility
89.64355152
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Cidara Therapeutics financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Cidara Therapeutics' main balance sheet or income statement drivers, such as Interest Expense of 210.4 K, Selling General Administrative of 14 M or Other Operating Expenses of 63.2 M, as well as many indicators such as Price To Sales Ratio of 1.03, Dividend Yield of 0.0 or Days Sales Outstanding of 111. Cidara financial statements analysis is a perfect complement when working with Cidara Therapeutics Valuation or Volatility modules.
  
Check out the analysis of Cidara Therapeutics Correlation against competitors.
For more information on how to buy Cidara Stock please use our How to Invest in Cidara Therapeutics guide.

Latest Cidara Therapeutics' Days Of Sales Outstanding Growth Pattern

Below is the plot of the Days Of Sales Outstanding of Cidara Therapeutics over the last few years. It is Cidara Therapeutics' Days Of Sales Outstanding historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Cidara Therapeutics' overall financial position and show how it may be relating to other accounts over time.
Days Of Sales Outstanding10 Years Trend
Slightly volatile
   Days Of Sales Outstanding   
       Timeline  

Cidara Days Of Sales Outstanding Regression Statistics

Arithmetic Mean41.06
Geometric Mean1.38
Coefficient Of Variation218.33
Mean Deviation55.79
Median0.17
Standard Deviation89.64
Sample Variance8,036
Range338
R-Value0.47
Mean Square Error6,703
R-Squared0.23
Significance0.07
Slope9.52
Total Sum of Squares112,504

Cidara Days Of Sales Outstanding History

2024 110.78
2023 92.79
2022 33.12
2021 39.44
2020 338.02

About Cidara Therapeutics Financial Statements

Cidara Therapeutics investors use historical fundamental indicators, such as Cidara Therapeutics' Days Of Sales Outstanding, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Cidara Therapeutics. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Days Of Sales Outstanding 92.79  110.78 

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Cidara Stock Analysis

When running Cidara Therapeutics' price analysis, check to measure Cidara Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Cidara Therapeutics is operating at the current time. Most of Cidara Therapeutics' value examination focuses on studying past and present price action to predict the probability of Cidara Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Cidara Therapeutics' price. Additionally, you may evaluate how the addition of Cidara Therapeutics to your portfolios can decrease your overall portfolio volatility.